Skip to content

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

News

Select Year
Clinical Trials
Search …

May 2, 2007

Oncolytics Biotech Inc. Announces Details of 2007 Annual Shareholder Meeting

April 30, 2007

Oncolytics Biotech Inc. Successfully Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R)

April 27, 2007

Oncolytics Biotech Inc. Announces 2007 First Quarter Results

April 17, 2007

Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines

April 11, 2007

Oncolytics Biotech Inc. Proceeds to Initiate U.S. Phase II Sarcoma Clinical Trial

April 3, 2007

Oncolytics Biotech Inc. Announces Issuance of 20th U.S. Patent

March 21, 2007

Oncolytics Biotech Inc. Announces Closing of Over-Allotment Option

March 19, 2007

Oncolytics Biotech Inc. Research Collaborators Present Combination Reovirus and Cyclophosphamide Treatment Results at International Oncolytic Virus Conference

March 16, 2007

Oncolytics Biotech Inc. Research Collaborators to Present Reovirus Treatment in Melanoma Animal Models at International Oncolytic Virus Conference

March 16, 2007

Oncolytics Biotech Inc. Research Collaborators to Present Combination Reovirus and Cisplatin Treatment Results at Oncolytic Virus Conference

Page 67 of 69

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.ca

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Loading...

4350 Executive Drive
Suite 325
San Diego, CA 92121
info@oncolyticsbiotech.com

Company

About Us
Leadership
Scientific Advisors
Careers
Contact

Science

Our Science
Pipeline
Publications

Investors

Overview
News
Events
Stock Information
Filings
Corporate Governance
FAQs

Privacy Policy Accessibility Cookie Policy Disclaimer Sitemap Manage Consent

Copyright © 2025 Oncolytics Biotech Inc.